The company, based in Amsterdam, develops gene therapies. It raised $91.8 million after offering 5.4 million shares at $17 per share. It will use the money raised to finish building a manufacturing facility in Lexington, Mass., and for clinical trials. Its shares are listed on the Nasdaq under the ticker symbol "QURE." They fell $2.39, or 14.1 percent, to $14.61.
uniQure B.V.
Meibergdreef 61
Amsterdam, 1105 BA
Netherlands
Website: http://www.uniqure.com
| Business Summary |
|---|
uniQure BV, a biopharmaceutical company, develops gene therapies through its modular technology platform for the treatment of genetic or acquired diseases. The company offers Glybera for the treatment of patients with lipoprotein lipase deficiency, an orphan metabolic disease. It also develops a pipeline of additional adeno-associated virus (AAV) based gene therapies, including AMT-060, a gene therapy for the treatment of hemophilia B; AMT-021 for acute intermittent porphyria; AMT-110 for Sanfilippo B syndrome; and AAV2/glial cell line-derived neurotrophic factor for Parkinson's disease, as well as various programs that are in early preclinical development stage. The company has collaborations with Chiesi Farmaceutici S.p.A., Digna Biotech, Institut Pasteur, and University of California San Francisco. uniQure BV was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
No comments:
Post a Comment